234 related articles for article (PubMed ID: 19321861)
21. B-cell maturation antigen (BCMA) activation exerts specific proinflammatory effects in normal human keratinocytes and is preferentially expressed in inflammatory skin pathologies.
Alexaki VI; Pelekanou V; Notas G; Venihaki M; Kampa M; Dessirier V; Sabour-Alaoui S; Stathopoulos EN; Tsapis A; Castanas E
Endocrinology; 2012 Feb; 153(2):739-49. PubMed ID: 22166983
[TBL] [Abstract][Full Text] [Related]
22. TACI deficiency leads to alternatively activated macrophage phenotype and susceptibility to Leishmania infection.
Allman WR; Dey R; Liu L; Siddiqui S; Coleman AS; Bhattacharya P; Yano M; Uslu K; Takeda K; Nakhasi HL; Akkoyunlu M
Proc Natl Acad Sci U S A; 2015 Jul; 112(30):E4094-103. PubMed ID: 26170307
[TBL] [Abstract][Full Text] [Related]
23. Lymphoma B cells evade apoptosis through the TNF family members BAFF/BLyS and APRIL.
He B; Chadburn A; Jou E; Schattner EJ; Knowles DM; Cerutti A
J Immunol; 2004 Mar; 172(5):3268-79. PubMed ID: 14978135
[TBL] [Abstract][Full Text] [Related]
24. TLR stimulation modifies BLyS receptor expression in follicular and marginal zone B cells.
Treml LS; Carlesso G; Hoek KL; Stadanlick JE; Kambayashi T; Bram RJ; Cancro MP; Khan WN
J Immunol; 2007 Jun; 178(12):7531-9. PubMed ID: 17548587
[TBL] [Abstract][Full Text] [Related]
25. APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications.
Tai YT; Lin L; Xing L; Cho SF; Yu T; Acharya C; Wen K; Hsieh PA; Dulos J; van Elsas A; Munshi N; Richardson P; Anderson KC
Leukemia; 2019 Feb; 33(2):426-438. PubMed ID: 30135465
[TBL] [Abstract][Full Text] [Related]
26. Transmembrane activator and calcium-modulating cyclophilin ligand interactor mutations in common variable immunodeficiency: clinical and immunologic outcomes in heterozygotes.
Zhang L; Radigan L; Salzer U; Behrens TW; Grimbacher B; Diaz G; Bussel J; Cunningham-Rundles C
J Allergy Clin Immunol; 2007 Nov; 120(5):1178-85. PubMed ID: 17983875
[TBL] [Abstract][Full Text] [Related]
27. The role of the BAFF/APRIL system in the T cell-independent specific response to blood stage Plasmodium falciparum hemozoin.
Dechkajorn W; Benjathummarak S; Kumsiri R; Maneerat Y
Cytokine; 2018 Nov; 111():445-453. PubMed ID: 29884307
[TBL] [Abstract][Full Text] [Related]
28. BAFF-R and TACI expression on CD3+ T cells: Interplay among BAFF, APRIL and T helper cytokines profile in systemic lupus erythematosus.
Salazar-Camarena DC; Ortíz-Lazareno P; Marín-Rosales M; Cruz A; Muñoz-Valle F; Tapia-Llanos R; Orozco-Barocio G; Machado-Contreras R; Palafox-Sánchez CA
Cytokine; 2019 Feb; 114():115-127. PubMed ID: 30467093
[TBL] [Abstract][Full Text] [Related]
29. The proteoglycan (heparan sulfate proteoglycan) binding domain of APRIL serves as a platform for ligand multimerization and cross-linking.
Kimberley FC; van Bostelen L; Cameron K; Hardenberg G; Marquart JA; Hahne M; Medema JP
FASEB J; 2009 May; 23(5):1584-95. PubMed ID: 19141538
[TBL] [Abstract][Full Text] [Related]
30. Transmembrane activator and calcium modulator and cyclophilin ligand interactor enhances CD40-driven plasma cell differentiation.
Castigli E; Wilson SA; Elkhal A; Ozcan E; Garibyan L; Geha RS
J Allergy Clin Immunol; 2007 Oct; 120(4):885-91. PubMed ID: 17689597
[TBL] [Abstract][Full Text] [Related]
31. TACI, isotype switching, CVID and IgAD.
Castigli E; Geha RS
Immunol Res; 2007; 38(1-3):102-11. PubMed ID: 17917015
[TBL] [Abstract][Full Text] [Related]
32. Silencing of the cytokine receptor TNFRSF13B: A new therapeutic target for triple-negative breast cancer.
Abo-Elfadl MT; Gamal-Eldeen AM; Ismail MF; Shahin NN
Cytokine; 2020 Jan; 125():154790. PubMed ID: 31400636
[TBL] [Abstract][Full Text] [Related]
33. Toll-like receptor 9, transmembrane activator and calcium-modulating cyclophilin ligand interactor, and CD40 synergize in causing B-cell activation.
Ozcan E; Rauter I; Garibyan L; Dillon SR; Geha RS
J Allergy Clin Immunol; 2011 Sep; 128(3):601-9.e1-4. PubMed ID: 21741080
[TBL] [Abstract][Full Text] [Related]
34. In Silico Identification of Novel APRIL Peptide Antagonists and Binding Insights by Molecular Modeling and Immunosorbent Assays.
Silva JH; Calmon-Hamaty F; Savino W; Hahne M; Caffarena ER
Protein Pept Lett; 2015; 22(5):432-42. PubMed ID: 25731591
[TBL] [Abstract][Full Text] [Related]
35. TACI mutations and impaired B-cell function in subjects with CVID and healthy heterozygotes.
Martinez-Gallo M; Radigan L; Almejún MB; Martínez-Pomar N; Matamoros N; Cunningham-Rundles C
J Allergy Clin Immunol; 2013 Feb; 131(2):468-76. PubMed ID: 23237420
[TBL] [Abstract][Full Text] [Related]
36. Syk-dependent mTOR activation in follicular lymphoma cells.
Leseux L; Hamdi SM; Al Saati T; Capilla F; Recher C; Laurent G; Bezombes C
Blood; 2006 Dec; 108(13):4156-62. PubMed ID: 16912221
[TBL] [Abstract][Full Text] [Related]
37. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
Gao N; Flynn DC; Zhang Z; Zhong XS; Walker V; Liu KJ; Shi X; Jiang BH
Am J Physiol Cell Physiol; 2004 Aug; 287(2):C281-91. PubMed ID: 15028555
[TBL] [Abstract][Full Text] [Related]
38. APRIL promotes proliferation, secretion and invasion of fibroblast-like synoviocyte from rats with adjuvant induced arthritis.
Chang Y; Jia X; Sun X; Xu S; Wu Y; Zhang L; Wei W
Mol Immunol; 2015 Mar; 64(1):90-8. PubMed ID: 25466610
[TBL] [Abstract][Full Text] [Related]
39. mTOR intersects antibody-inducing signals from TACI in marginal zone B cells.
Sintes J; Gentile M; Zhang S; Garcia-Carmona Y; Magri G; Cassis L; Segura-Garzón D; Ciociola A; Grasset EK; Bascones S; Comerma L; Pybus M; Lligé D; Puga I; Gutzeit C; He B; DuBois W; Crespo M; Pascual J; Mensa A; Aróstegui JI; Juan M; Yagüe J; Serrano S; Lloreta J; Meffre E; Hahne M; Cunningham-Rundles C; Mock BA; Cerutti A
Nat Commun; 2017 Nov; 8(1):1462. PubMed ID: 29133782
[TBL] [Abstract][Full Text] [Related]
40. Expression and characterization of a variant of TACI (CRD2-shortTACIFc) in Pichia pastoris.
Wang R; Zhou S; Peng X; Zhou XW; Xie ZQ; Wang Y; Mo W; Yu M
Protein Pept Lett; 2012 Mar; 19(3):315-25. PubMed ID: 21933134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]